Chemical Compound

Galantamine

Galantamine

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

16-24 mg/day

watchEffect Window

Clinical effects are evaluated over weeks to months. Trial outcomes commonly reported at 3-6 months.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Galantamine is a prescription acetylcholinesterase inhibitor and nicotinic receptor modulator used in Alzheimer’s disease. It is used to improve cognitive symptoms by enhancing cholinergic transmission.

Clinical trials show modest improvements in cognition and daily function in mild-to-moderate Alzheimer’s disease. Mechanistically, it increases acetylcholine availability and modulates nicotinic receptors. Minority interest includes lucid dreaming and cognitive enhancement, but evidence is weak and risks increase outside clinical supervision. Benefits are best supported in diagnosed dementia populations under medical care.

Reversible acetylcholinesterase inhibition plus nicotinic receptor allosteric modulation. Effects are symptomatic and dose-dependent with significant cholinergic adverse effects during titration.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Slower ADAS-cog/11 decline vs placebo in mild-to-moderate AD at 6 months
  • Lower CIBIC-plus/CIBIC-like global impairment progression at 6 months in pooled data
  • Reduced functional decline signal on DAD/ADL measures

Secondary Outcomes

  • No consistent MCI conversion reduction over 24 months
  • Mixed CDR-sum and cognitive subscale findings in MCI
  • No disease-modifying evidence in available clinical literature

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy
  • Lactation
  • High-risk comorbid disease

Side effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Dizziness
  • Decreased appetite

Interactions

  • Other cholinesterase inhibitors
  • Anticholinergic burden
  • Arrhythmia-risk medicines

Avoid if

  • Active severe cardiac conduction disease
  • Severe hepatic/renal impairment
  • Severe GI obstruction or ulcer risk
  • Current severe urinary retention

Evidence

Study-level References

galantamine-SRC-001Systematic review/meta-analysis of randomized placebo-controlled galantamine trials
Sourceopen_in_new

Lim AW, Schneider L, Loy C. Cochrane Database Syst Rev. 2024; Issue 11. Art. No.: CD001747.

Population: Mild-to-moderate Alzheimer disease (10,990 participants across 21 studies) and mild cognitive impairment cohorts

Dose protocol: Mostly 16-24 mg/day, 4-12 month and up to 2-year follow-up

Key findings: Reduced attrition-adjusted decline in cognition and behavior in Alzheimer populations at 6 months. Unclear conversion benefit in MCI. GI adverse events significantly more frequent in active groups.

Notes: Evidence for MCI remains methodologically constrained by discontinuation imbalance and long-term follow-up imprecision.

Paper content

Reduced attrition-adjusted decline in cognition and behavior in Alzheimer populations at 6 months; unclear conversion benefit in MCI; GI adverse events significantly more frequent in active groups.

galantamine-SRC-002Randomized, double-blind, placebo-controlled trial (multicenter)
Sourceopen_in_new

Wilcock GK et al. BMJ. 2000;321(7274):1445. doi:10.1136/bmj.321.7274.1445.

Population: Mild-to-moderate Alzheimer disease (n=653)

Dose protocol: Titrated from 8 mg/day (week 1) to 16 mg/day (week 2), to 24 mg/day (week 3), then 24 or 32 mg/day maintenance

Key findings: Galantamine improved ADAS-cog/11, CIBIC-plus, and DAD outcomes at 6 months versus placebo. Dose escalation-related adverse events were common.

Notes: Supports pooled estimates but does not directly support use in non-AD populations.

Paper content

Galantamine improved ADAS-cog/11, CIBIC-plus, and DAD outcomes at 6 months versus placebo; dose escalation-related adverse events were common.

galantamine-SRC-003Randomized, double-blind comparative studies/meta-eligible MCI trial data
Sourceopen_in_new

Winblad B et al. Neurology. 2008;70(22):2024-35. doi:10.1212/01.wnl.0000303815.69777.26.

Population: Mild cognitive impairment (combined n=2048; CDR 0.5)

Dose protocol: 16-24 mg/day for 24 months

Key findings: No significant difference in conversion rates to dementia in pooled MCI analyses. Nausea rates were high and serious adverse events were balanced.

Notes: Conversion signal is weak and not sufficiently strong for routine off-label nootropic recommendations.

Paper content

No significant difference in conversion rates to dementia in pooled MCI analyses; nausea rates were high and serious adverse events were balanced.

galantamine-SRC-005Double-blind, randomized, placebo-controlled crossover trial.
Sourceopen_in_new

Yadav A, Stephens-Shields AJ, Karaj A, et al. Galantamine for 12 weeks does not improve neurocognition or immune activation in ART-suppressed people with HIV. AIDS. 2026;40(5). doi:10.1097/QAD.0000000000004418. PMID:41427614.

Population: Adults with HIV on antiretroviral therapy, including smokers and non-smokers.

Dose protocol: Galantamine versus placebo for 12 weeks in a double-blind crossover design

Key findings: No neurocognitive improvement. Monocyte CCR2 expression increased 15.2% (P=0.006) but other immune markers were unchanged. Some pro-inflammatory cytokines increased.

Notes: Well-designed negative result that helps define the boundaries of galantamine's cognitive benefit to Alzheimer's populations.

Paper content

This double-blind crossover RCT tested 12 weeks of galantamine versus placebo in ART-suppressed people with HIV. The primary neurocognitive outcome showed no significant improvement with galantamine. Among immune markers, monocyte CCR2 expression was 15.2% higher with galantamine (P=0.006), but no differences were seen in CD16, CD163, CD8+ T-cell activation, or plasma markers. Some pro-inflammatory cytokines actually increased with treatment. The trial is relevant as a well-designed negative result, showing that galantamine does not reliably improve cognition or reduce immune activation in HIV-associated neurocognitive impairment. This adds to the evidence that galantamine's cognitive benefits are limited to Alzheimer's disease populations.

galantamine-SRC-004Mechanistic pharmacology study
Sourceopen_in_new

Samochocki M et al. J Pharmacol Exp Ther. 2003;305(3):1024-1036. doi:10.1124/jpet.102.045773.

Population: Ex vivo and receptor-level models with translational relevance to cholinergic physiology

Dose protocol: Concentration range 0.1-1 μM modeled around CSF exposures at 16-24 mg/day

Key findings: Demonstrated nicotinic receptor allosteric potentiation and preferential cholinergic modulation in addition to reversible AChE inhibition.

Notes: Mechanistic evidence supports rationale but is not a direct clinical outcome.

Paper content

Demonstrated nicotinic receptor allosteric potentiation and preferential cholinergic modulation in addition to reversible AChE inhibition.

Guides

Setup

Help